Trials / Conditions / CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
3 registered clinical trials studyying CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Su NCT06881017 | China Medical University, China | Phase 2 |
| Completed | Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gast NCT01671774 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer NCT01630083 | Astellas Pharma Global Development, Inc. | Phase 2 |